(Seoul=NSP News Agency) hYUNJIN KIM Journalist = KT invests five million U.S. dollars in the Phase A series of the U.S. electroceuticals company NeuroSigma.
NeuroSigma is specialized in electroceuticals treating neuropsychiatric diseases, including ADHD, depression, epilepsy, using electric patches to stimulate cranial nerves.
Its 2019-developed Monarch external Trigeminal Nerve Stimulation System (eTNS) is the first electroceuticals for neuropsychiatric diseases approved by the FDA as an alternative for medicine. Based on the investment, the electroceuticals company will promote the commercialization of the product in the American market.
NeuroSigma is specialized in electroceuticals treating neuropsychiatric diseases, including ADHD, depression, epilepsy, using electric patches to stimulate cranial nerves.
Its 2019-developed Monarch external Trigeminal Nerve Stimulation System (eTNS) is the first electroceuticals for neuropsychiatric diseases approved by the FDA as an alternative for medicine. Based on the investment, the electroceuticals company will promote the commercialization of the product in the American market.
광고를 불러오는 중...
Based on its AI, Big data, cloud technologies, KT will support designing and developing the next generation eTNS and will promote upgrading monitoring and AI analysis services linked to the KT digital healthcare platform.
![[NSPAD]삼성전자](https://file.nspna.com/ad/T01_samsung_gn_5138.gif "삼성전자[T01]")